 |
 |

Editor's Comment
Michael Bigby, MD
Arch Dermatol. 2002;138:1233.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In this article, Pelle and Callen report a strong association between
the development of rash in patients with dermatomyositis who take hydroxychloroquine
compared with similarly exposed patients with lupus. The criteria to appraise
the validity of such a study about harm include similarity of the comparison
groups with respect to important determinants of outcome; similar measurement
of outcome and exposure in the groups; sufficient length of follow-up; and
correct temporal relationship between exposure and adverse events (Levine
M, Walter S, Lee H, Haines T, Holbrook A, Moyer V, for the Evidence-Based
Medicine Working Group. Users' guides to the medical literature, IV: how to
use an article about harm. JAMA. 1994;271:1615-1619). This study meets these
quality criteria quite well. The strength of association in case-control studies
is typically expressed as the odds ratio and its 95% confidence interval (12
[1.8 to 525] in this study). Pelle and . . . [Full Text of this Article]
|